News | February 20, 2023
India achieves 15,000+ transplants in a year
There is a fast resurgence in the transplant activities post COVID
There is a fast resurgence in the transplant activities post COVID
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
The organisation is also working towards providing skills based training programmes to the workers for paramedical jobs and has launched certificate courses in ten disciplines
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
It offers quick relief in various types of Coughs, Colds and Sore Throat,
The Group will continue to make proactive investments of its management resources in the life science business
Subscribe To Our Newsletter & Stay Updated
